Our mission is to ensure the generation of accurate and precise findings.

GET UPDATE

Please enter subscribe form shortcode

CHEACK INSTAGRAM POST

Please enter instagram feed shortcode

Our R&D Studies

Thorvacs LTD aims to develop highly effective biologically based next generation vaccine adjuvants safeguarding humans and animals against several life-threatening and economically damaging diseases.

Use of Various TLR Agonists as Adjuvants in improving Food & Mouth Disease Efficacy, Supported by the Ministry of Science, Industry and Technology, Techno-initiative Fund. (2013)

Use of CpG ODN’s as adjuvants in Avian Salmonella vaccine formulations. Supported by the Ministry of Science, Industry and Technology, Techno-initiative Fund. (2014)
Development of adjuvants for use in increasing vaccine efficacy. (2014)

Development of prostate cancer detection kits using extracellular vesicles in urine. Funded by the 1512 Entrepreneurial Support Program (2014)
Nucleic acid based protective and therapeutic Hepatits B vaccine (2017)
Personalized exosome based therapeutic cancer vaccine (2019)
Next generation Avian Salmonella Vaccine Development. Funded by the KOSGEB R&D Innovation Funding Program (2020)

Development of ELISA & Flow Cytometry Diagnostic Kits for COVID-19. Funded by the Turkish FDA 1501 Coded Industry R&D Support Program. (2021)

Development of Cytokine and Kemokine pre-coated ELISA plates for Research (2023)